A Phase 1 interventional study of Abemaciclib and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-04.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purposes of this study are to determine:
Information about any side effects that occur will be collected. The study will enroll two groups (cohorts) of participants. Each group will complete 4 study periods. This study is expected to last about 3 months. Screening may occur up to 28 days prior to enrollment. All participants will undergo a follow-up assessment approximately 21 days after administration of their final dose of study drug.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Overtly healthy males or females, as determined by medical history and physical examination
Exclusion Criteria:
Additional Exclusion Criterion for Participants Enrolled in Cohort 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 - 600 mg single increasing oral dose of abemaciclib on Day 1 of up to 3 study periods.
Drug: Abemaciclib
Single oral dose of placebo on Day 1 of 1 study period.
Drug: Placebo
Cohort 2, only. 8 mg Loperamide given orally once in 1 of 4 study periods.
Drug: Loperamide
Cohort 2, only. 8 mg Loperamide co-administered with abemaciclib given orally once in up to 1 of 4 study periods.
Drug: Abemaciclib · Drug: Loperamide
Cohort 2, only. 8 mg Loperamide co-administered with placebo given orally once in up to 1 of 4 study periods.
Drug: Placebo · Drug: Loperamide
Administered orally
Also known as: LY2835219
Administered orally
Administered orally
Mean Time Matched Placebo-Adjusted Changes From Baseline For Fridericia's Corrected QT Interval (ΔΔQTcF)
QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data. ECG monitoring was conducted using a 12-lead digital Holter recorder from approximately 2 hours predose through 24 hours postdose on Day 1 of each period using 12-lead digital Holter recorder. Fridericia-corrected QT interval (QTcF): QTcF = QT/RR1/3, where RR is the interval between two R waves.
Time frame: Day 1: 2hr,4hr,6hr,8hr,10hr,12hr,14hr,24hr Post Dose
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib
Blood samples were collected from participants in Cohort 1(all periods) and Cohort 2 (Periods 5, 6, and 7) to determine the plasma concentrations of Abemaciclib.
Time frame: Day 1: 2, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, and 120 hours Post Dose
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Last Time Point With Measurable Concentration AUC(0-tlast) of Abemaciclib
Blood samples were collected from participants in Cohort 1(all periods) and Cohort 2 (Periods 5, 6, and 7) to determine the plasma concentrations of Abemaciclib 0-tlast.
Time frame: Day 1: 2, 4, 6, 8, 10, 12, 14, 24, 48, 72, 96, and 120 hours Post Dose
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point With Measurable Concentration [AUC(0-tlast)] of Loperamide
Blood samples were collected from participants in Cohort 2 Period 4 (DDI) to determine plasma concentrations of Loperamide.
Time frame: Day -3: Predose, 1, 2, 4, 6, 8, 12, 14, 24, and 48 hours postdose;Day 1 predose, (-0.25 hours), and Day1: 1, 2, 4, 6, 8, 10, 12, 14, 24, 48, and 72 hours Post Dose
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Loperamide
Blood samples were collected from participants in Cohort 2 Period 4 (DDI) to determine plasma concentrations of Loperamide.
Time frame: Day -3: Predose,1, 2, 4, 6, 8, 12, 14, 24, and 48 hours postdose;Day 1 predose, (-0.25 hours), and Day1: 1, 2, 4, 6, 8, 10, 12, 14, 24, 48, and 72 hours Post Dose
Dose escalation study with 2 cohorts, participants in cohort 1 were randomized to 1 of 4 sequences \& participants in cohort 2 were randomized to 1 of 3 sequences. Cohort 1 had periods 1 to 4 with at least 5 days washout between each dose, Cohort 2 had periods 4(DDI) to 7 with at least 8 days washout between each dose.
| Milestone | Cohort 1 Sequence 1 | Cohort 1 Sequence 2 | Cohort 1 Sequence 3 | Cohort 1 Sequence 4 | Cohort 2 Sequence 1 | Cohort 2 Sequence 2 | Cohort 2 Sequence 3 |
|---|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 0 | 0 | 0 |
| Completed | 5 | 5 | 5 | 5 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 Sequence 1 | Cohort 1 Sequence 2 | Cohort 1 Sequence 3 | Cohort 1 Sequence 4 | Cohort 2 Sequence 1 | Cohort 2 Sequence 2 | Cohort 2 Sequence 3 |
|---|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 0 | 0 | 0 |
| Completed | 5 | 5 | 5 | 5 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 Sequence 1 | Cohort 1 Sequence 2 | Cohort 1 Sequence 3 | Cohort 1 Sequence 4 | Cohort 2 Sequence 1 | Cohort 2 Sequence 2 | Cohort 2 Sequence 3 |
|---|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 0 | 0 | 0 |
| Completed | 5 | 5 | 5 | 4 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Cohort 1 Sequence 1 | Cohort 1 Sequence 2 | Cohort 1 Sequence 3 | Cohort 1 Sequence 4 | Cohort 2 Sequence 1 | Cohort 2 Sequence 2 | Cohort 2 Sequence 3 |
|---|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 4 | 0 | 0 | 0 |
| Completed | 5 | 5 | 5 | 4 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 Sequence 1 | Cohort 1 Sequence 2 | Cohort 1 Sequence 3 | Cohort 1 Sequence 4 | Cohort 2 Sequence 1 | Cohort 2 Sequence 2 | Cohort 2 Sequence 3 |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 7 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 7 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 Sequence 1 | Cohort 1 Sequence 2 | Cohort 1 Sequence 3 | Cohort 1 Sequence 4 | Cohort 2 Sequence 1 | Cohort 2 Sequence 2 | Cohort 2 Sequence 3 |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 7 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 7 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 Sequence 1 | Cohort 1 Sequence 2 | Cohort 1 Sequence 3 | Cohort 1 Sequence 4 | Cohort 2 Sequence 1 | Cohort 2 Sequence 2 | Cohort 2 Sequence 3 |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 7 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 7 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 Sequence 1 | Cohort 1 Sequence 2 | Cohort 1 Sequence 3 | Cohort 1 Sequence 4 | Cohort 2 Sequence 1 | Cohort 2 Sequence 2 | Cohort 2 Sequence 3 |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 7 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 | 7 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data. ECG monitoring was conducted using a 12-lead digital Holter recorder from approximately 2 hours predose through 24 hours postdose on Day 1 of each period using 12-lead digital Holter recorder. Fridericia-corrected QT interval (QTcF): QTcF = QT/RR1/3, where RR is the interval between two R waves.
| Millisecond (msec) | 200 mg Abemaciclib | 300 mg Abemaciclib | 400 mg Abemaciclib | 600 mg Abemaciclib |
|---|---|---|---|---|
| 2hr | 1.4 (-0.4 to 4.8) | 3.3 (-2.1 to 4.3) | 0.2 (-3.7 to 1.3) | -2.1 (-7.3 to 0.6) |
| 4hr | -2.0 (-5.1 to 1.6) | 0.8 (-4.5 to 0.8) | -0.7 (-4.9 to 0.6) | -4.2 (-9.9 to 0.9) |
| 6hr | 0.6 (-1.5 to 5.2) | -0.2 (-5.8 to 1.2) | -1.8 (-5.9 to -0.1) | -3.7 (-10.3 to -0.8) |
| 8hr | 2.8 (0.7 to 6.4) | 2.7 (-3.1 to 4.0) | 2.2 (-1.8 to 3.5) | 2.8 (-3.9 to 5.8) |
| 10hr | 2.1 (0.6 to 5.1) | 1.3 (-3.7 to 1.7) | 1.5 (-2.4 to 2.1) | 5.9 (-2.8 to 11) |
| 12hr | -0.3 (-4.7 to 5.6) | -0.7 (-6.6 to 0.8) | -0.5 (-4.4 to 0.1) | 4.4 (-0.9 to 7.2) |
| 14hr | 3.9 (1.4 to 7.9) | 3.3 (-2.1 to 4.1) | 1.0 (-3.9 to 2.6) | 2.3 (-4.4 to 5.4) |
| 24hr | 1.4 (-1.2 to 5.5) | 4.2 (-0.7 to 4.8) | -0.4 (-4.7 to 1.3) | 0.9 (-7.1 to 4.6) |
Blood samples were collected from participants in Cohort 1(all periods) and Cohort 2 (Periods 5, 6, and 7) to determine the plasma concentrations of Abemaciclib.
| Nanogram per Milliliter (ng/mL) | 200 mg Abemaciclib | 300 mg Abemaciclib | 400 mg Abemaciclib | 600 mg Abemaciclib | 400 mg Abemaciclib + Loperamide 8mg |
|---|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib | 102 ± 31 | 130 ± 40 | 182 ± 42 | 308 ± 45 | 199 ± 55 |
Blood samples were collected from participants in Cohort 1(all periods) and Cohort 2 (Periods 5, 6, and 7) to determine the plasma concentrations of Abemaciclib 0-tlast.
| ng*hr/mL | 200 mg Abemaciclib | 300 mg Abemaciclib | 400 mg Abemaciclib | 600 mg Abemaciclib | 400 mg Abemaciclib + 8 mg Loperamide |
|---|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to Last Time Point With Measurable Concentration AUC(0-tlast) of Abemaciclib | 3560 ± 38 | 5210 ± 37 | 7610 ± 46 | 14600 ± 42 | 9420 ± 57 |
Blood samples were collected from participants in Cohort 2 Period 4 (DDI) to determine plasma concentrations of Loperamide.
| ng*hr/mL | 8 mg Loperamide | 8 mg Loperamide + 400 mg Abemaciclib |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point With Measurable Concentration [AUC(0-tlast)] of Loperamide | 46.1 ± 47 | 47.3 ± 53 |
Blood samples were collected from participants in Cohort 2 Period 4 (DDI) to determine plasma concentrations of Loperamide.
| ng/mL | 8 mg Loperamide | 8 mg Loperamide + 400 mg Abemaciclib |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Loperamide | 1.83 ± 56 | 2.17 ± 49 |
Collected over Up to 117 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/34 (0%) | 9/34 (26.5%) |
| 200 mg Abemaciclib | — | 0/20 (0%) | 4/20 (20%) |
| 300 mg Abemaciclib | — | 0/20 (0%) | 5/20 (25%) |
| 400 mg Abemaciclib | — | 0/35 (0%) | 17/35 (48.6%) |
| 600 mg Abemaciclib | — | 0/15 (0%) | 12/15 (80%) |
| 8 mg Loperamide | — | 0/15 (0%) | 5/15 (33.3%) |
| 8 mg Loperamide + Placebo | — | 0/7 (0%) | 3/7 (42.9%) |
| 8 mg Loperamide + 400 mg Abemaciclib | — | 0/8 (0%) | 3/8 (37.5%) |
| Event | Placebo | 200 mg Abemaciclib | 300 mg Abemaciclib | 400 mg Abemaciclib | 600 mg Abemaciclib | 8 mg Loperamide | 8 mg Loperamide + Placebo | 8 mg Loperamide + 400 mg Abemaciclib |
|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/34 | 1/20 | 4/20 | 11/35 | 11/15 | 0/15 | 0/7 | 1/8 |
| NauseaGastrointestinal disorders | 0/34 | 3/20 | 0/20 | 6/35 | 8/15 | 0/15 | 1/7 | 2/8 |
| VomitingGastrointestinal disorders | 1/34 | 1/20 | 0/20 | 2/35 | 6/15 | 0/15 | 0/7 | 1/8 |
| ConstipationGastrointestinal disorders | 0/34 | 0/20 | 0/20 | 0/35 | 0/15 | 2/15 | 2/7 | 0/8 |
| Alanine aminotransferase increasedInvestigations | 0/34 | 0/20 | 0/20 | 0/35 | 0/15 | 0/15 | 2/7 | 2/8 |
| Aspartate aminotransferase increasedInvestigations | 0/34 | 0/20 | 0/20 | 0/35 | 0/15 | 0/15 | 2/7 | 2/8 |
| HeadacheNervous system disorders | 3/34 | 1/20 | 0/20 | 3/35 | 4/15 | 0/15 | 0/7 | 0/8 |
| Abdominal painGastrointestinal disorders | 0/34 | 0/20 | 0/20 | 1/35 | 1/15 | 1/15 | 0/7 | 2/8 |
| DizzinessNervous system disorders | 1/34 | 0/20 | 0/20 | 1/35 | 1/15 | 0/15 | 0/7 | 2/8 |
| FlatulenceGastrointestinal disorders | 2/34 | 0/20 | 0/20 | 0/35 | 1/15 | 0/15 | 1/7 | 0/8 |
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Mean | 48.9 ± 7.9 | 58 ± 7.5 | 52.8 ± 8.9 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Female | 15 | 13 | 28 |
| Male | 5 | 2 | 7 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 18 | 14 | 32 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| United States | 20 | 15 | 35 |
| Ethnicity(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 0 | 10 |
| Not Hispanic or Latino | 10 | 15 | 25 |
| Body Mass Index (BMI)(Kilogram per square meter (Kg/m^2)) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Mean | 26.80 ± 3.15 | 27.55 ± 2.35 | 27.12 ± 2.82 |
The record gives a start of Feb 2016, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abemaciclib · Loperamide